US equities
|
SPCX
$168.87
▲+6.23%
NVDA
$237.86
▲+1.67%
MU
$1,062.81
▼-1.12%
TSLA
$379.71
▲+2.46%
MSFT
$525.32
▲+1.51%
SNDK
$1,714.06
▼-0.35%
INTC
$117.04
▼-1.92%
META
$744.05
▲+2.19%
SPCX
$168.87
▲+6.23%
NVDA
$237.86
▲+1.67%
MU
$1,062.81
▼-1.12%
TSLA
$379.71
▲+2.46%
MSFT
$525.32
▲+1.51%
SNDK
$1,714.06
▼-0.35%
INTC
$117.04
▼-1.92%
META
$744.05
▲+2.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Kyverna Therapeutics, Inc. - Common Stock
(NQ:
KYTX
)
6.332
+0.112 (+1.80%)
Delayed Quote
Updated: 1:47 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kyverna Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
December 15, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Which stocks are moving on Monday?
↗
December 15, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy
December 15, 2025
Via
AB Newswire
Monday's session: top gainers and losers
↗
December 15, 2025
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Which stocks are gapping on Monday?
↗
December 15, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome?
↗
December 15, 2025
In the KYSA-8 trial, a single infusion of miv-cel delivered sustained improvements across both primary and secondary measures of Stiff Person Syndrome.
Via
Stocktwits
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
December 15, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
December 14, 2025
– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET –
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
November 20, 2025
Via
Benzinga
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
November 12, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
November 10, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
↗
November 04, 2025
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
Via
Benzinga
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
November 03, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
October 29, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
October 25, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
October 22, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Top movers in Wednesday's session
↗
October 08, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
October 02, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
September 24, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
September 15, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
August 28, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
August 25, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026
↗
August 20, 2025
William Blair starts Kyverna coverage with Outperform, citing KYV-101's potential as the first FDA-approved CAR-T therapy in autoimmune disease.
Via
Benzinga
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
August 12, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
July 15, 2025
Via
Benzinga
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 02, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
June 18, 2025
Via
Benzinga
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?
↗
May 27, 2025
HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027.
Via
Benzinga
This Commercial Metals Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
↗
May 27, 2025
Via
Benzinga
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 15, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
